Receptor for advanced glycation end products (RAGE) has been implicated in the 31 pathophysiology of AD due to its ability to bind amyloid-beta and mediate inflammatory 32 response. G82S RAGE polymorphism is associated with AD but the molecular mechanism for 33 this association is not understood. Our previous in silico study indicated a higher binding 34 affinity for mutated G82S RAGE, which could be caused due to changes in N linked 35 glycosylation at residue N81. To confirm this hypothesis, in the present study molecular 36 dynamics (MD) simulations were used to simulate the wild type (WT) and G82S glycosylated 37 structures of RAGE to identify the global structural changes and to find the binding efficiency 38 with Aβ42 peptide. Binding pocket analysis of the MD trajectory showed that cavity/binding 39 pocket in mutant G82S glycosylated RAGE variants is more exposed and accessible to external 40 ligands compared to WT RAGE, which can enhance the affinity of RAGE for Aβ. To validate 41 the above concept, an in vitro binding study was carried using SHSY5Y cell line expressing 42 recombinant WT and mutated RAGE variant individually to which HiLyte Fluor labeled Aβ42 43 was incubated at different concentrations. Saturated binding kinetics method was adopted to 44 determine the K d values for Aβ42 binding to RAGE. The K d value for Aβ42-WT and Aβ42-45 mutant RAGE binding were 92±40 nM (95% CI-52 to 152nM; R 2 -0.92) and 45±20 nM (95% 46 CI -29 to 64nM; R 2 -0.93), respectively. The K d value of <100nM observed for both variants 47 implicates RAGE as a high-affinity receptor for Aβ42 and mutant RAGE has higher affinity 48 compared to WT. The alteration in binding affinity is responsible for activation of the 49 inflammatory pathway as implicated by enhanced expression of TNFα and IL6 in mutant 50 RAGE expressing cell line which gives a mechanistic view for the G82S RAGE association 51 with AD. 52 54 Receptor for Advanced Glycation End-products (RAGE) belongs to the immunoglobulin 55 superfamily, which interacts with various ligands and plays an important role in several 56 pathological conditions [1]. Due to alternative splicing, various isoforms are generated such as 57 full-length RAGE (fRAGE), secretory RAGE (sRAGE) and dominant negative RAGE 58 (DNRAGE) and they bind to the ligands with similar affinity. The fRAGE consist of 59 extracellular, hydrophobic transmembrane, and cytoplasmic domains, whereas sRAGE lacks a 60 transmembrane domain. Extracellular domain has three immunoglobulins like domains namely 61 variable (V) domain and two constant (C1 & C2) domains. The structural analysis of the ligand-62 binding domain within the V-domain structure of fRAGE indicates a hydrophobic cavity that 63 is bordered by cationic residues and a flexible region (Thr55-Pro71). The flexible region 64 allows further plasticity within the hydrophobic cavity, thereby promoting hydrostatic 65 interactions with RAGE ligands [2,3] 66 Initiation of signal transduction upon the interaction of RAGE with its specific ligands helps 67 in physiological processes such as chemotaxis, angiogenesis, inflammation, apoptosis, and 68 proliferation [1,4]. The interaction of the same ligand with RAGE has different effects specific 69 to the cell physiology where the activation of NF-kB helps in the survival of some cells and 70 apoptosis of other cells [5]. As a multiligand receptor, fRAGE binds to the ligands like 71 advanced glycosylation end products (AGEs), s100/calgranulins, amyloid-beta (Aβ) and 72 amphoterin (HMGB1). Interaction of RAGE with AGEs results in acceleration of 73 polymerization of Aβ, which increases the accumulation of insoluble plaques of Aβ, thereby 74 enhances the risk of developing age-related disorders of CNS [6,7]. Excessive accumulation of 75 these ligands tends to increase the inflammatory response and ROS production, resulting in 76 cellular dysfunction. 77 RAGE, a potential contributor for neurodegeneration, has been implicated in accelerating 78 degeneration and inflammation in neuronal tissues. The detrimental action of RAGE is exerted 79 by its interaction with ligands which in turn activate the downstream pathways involving STAT, 80 JKN, and NF-kB. Therefore, it has been indicated that the polymorphism within the ligand-81 binding domain of RAGE is associated with the activation of signal transduction pathways. 82 There are several polymorphisms reported on the ligand-binding domain of RAGE. G82S 83 polymorphism is one of the most frequently and naturally occurring single nucleotide 84 polymorphisms (SNP) which enhances its affinity for ligand [8]. Thus, mutant expression shifts 85 the signaling processes increases inflammation and contribute to several pathological 86 conditions including Alzheimer's disease (AD). Association of G82S RAGE polymorphism 87 with AD is reported in Chinese [9,10], Korean [11] and the Turkish population [12]. Enhanced 88 interaction between Aβ and fRAGE results in the activation of amyloid precursor protein (APP) 89 cleaving enzyme that increases the production and the deposition of Aβ in the form of amyloid 90 plaques [13]. Besides this, increased transport of circulating Aβ into the brain would be 91 expected because RAGE has been shown to transport Aβ across the blood-brain barrier 92 into the brain [14]. The structural determinants involved in post-translational modifications, 93 such as N-glycans shown to affect RAGE binding and signaling, possibly by altering its 94 association with various cell surface molecules. The V-type ligand domain of RAGE has two 95 potential N-linked glycosylation sites (N25 and N81) and Srikrishna et al. [15] has 96
127 Na+ or Cl‫-‬ ions, and then concentrated to 154 mM NaCl and energy minimized using steepest 128 descent method. The energy minimized systems were equilibrated in the NVT ensemble 129 followed by an NPT ensemble for 100 ps. The production dynamics were done in an 130 isothermal-isobaric ensemble of 300K and 1 atm pressure for 50 ns. Both minimizations of 131 energy were terminated using a maximum force tolerance of 1000 kJ mol ‫-‬ 1 nm‫-‬ 1 . The 132 temperature, pressure, and NaCl concentration were chosen in such a way that mimics human 133 body conditions. The resultant trajectory was analyzed using VMD and cavity volumes were 134 tracked using MD pocket webserver with a grid spacing of 1Å 135 RAGE gene amplification and purification 136 The peripheral blood mononuclear cells (PBMC) were isolated by HiSep LSM density gradient The expected product size is 1215 base pairs. PCR was performed and the product was purified 148 from the 1% agarose gel using HiYield™ Gel/PCR DNA Mini Kit (Real Biotech Corporation, 149 Taiwan). HRP-conjugated rabbit anti-mouse antibody at a dilution of 1:100 and 1:500 respectively. The 
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RAGE-Aβ interaction in transfected cell line 217
The experiment was performed to analyze the specific binding of Aβ to WT and mutant RAGE. 218 We have used only Aβ42 since it is more pathogenic than other forms. To determine the optimal 219 concentration for Aβ treatment, recombinant SHSY5Y cells were incubated with varying Molecular dynamics has been carried out for 50 ns for both glycosylated form of WT and volumes were generated with an MD pocket using a grid spacing of 1 Å. It has been found that 283 the cavity/binding pocket in the polymorphic variant of glycosylated RAGE (G82S) is more 284 exposed /accessible to external ligands compared to WT RAGE which suggests that G82S 285 polymorphism enhances the ligand-binding affinity of RAGE ( Fig 2D) .
In the present modeling study, G82S RAGE glycosylated at N81 and N25 showed a more 
Site-directed mutagenesis of G82S RAGE gene confirmation 301
Genome-wide association study is widely conducted to help in developing a more accurate The gradient PCR with gene specific primers was used for amplification of fRAGE gene. The
308
PCR product was electrophoresed in 1% agarose gel. Expected product size of 1215bp 309 corresponding to fRAGE was observed in annealing temperature of 69 -72°C ( Fig 3A) . The To create the G82S mutant RAGE variant, the site-directed mutagenesis was performed in 337 pTZ57R/T with the WT RAGE construct ( Fig 4A) . western blotting of whole cell lysate (Figs 5A and B) . The presence of 45kDA and 54KDa 362 proteins indicates the expression of beta-actin and recombinant RAGE protein, which was 363 confirmed through western blotting. The ELISA result of cell lysate also showed increased 364 expression RAGE protein in transfected cells than non-transfected controls (Fig 5C) . The mean 365 fluorescent intensity was found to be 2-fold higher in transfected cell lines than empty vector- Aβ42 treated cells showed a marginal increase in expression ( Fig 8A) . 438 The RAGE receptor which binds to a variety of proinflammatory ligands transmits the signal 439 from the ligand to NFκB regulated cytokines production. To confirm the inflammatory pathway 440 activation due to RAGE-Aβ interaction, the cells were exposed to Aβ42 and tested for In our study, we report that G82S polymorphism stabilizes RAGE glycosylation at Asn81 457 suggesting that the increase in flexibility of the V-domain caused by the global destabilization 458 effect of G82S mutation might be the cause for more exposed binding cavity in polymorphic 459 glycosylated RAGE which enhances the ligand-binding affinity of RAGE towards Aβ. 460 Our study suggests that expression of RAGE is increased at sites of Aβ42 accumulation and 461 polymorphisms within ligand-binding regions (G82S) alters RAGE variant expressions leading 462 to enhanced fRAGE and decreased sRAGE expression thereby amplifying the inflammatory 463 response. These results cumulatively suggest that RAGE is a potential candidate for a 464 therapeutic approach in AD. This can be envisaged by using sRAGE therapeutically to clear 465 Aβ or by using antibody complimentary to Aβ binding region of fRAGE to prevent 466 inflammatory process in AD.
RAGE-Aβ interaction elicits inflammatory response
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